

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market.
Click for more information on our Core Candidates:
March 17 , 2010 - MediciNova Reports Positive Preliminary Results from a Phase Ib Clinical Trial of MN-221 in Moderate to Severe COPD Patients